ERBB2 and breast cancer: Phenotype-based classification in metastatic breast cancer using tumor tissue RNA expression profiling such as intrinsic subtyping (i.e., Luminal A, Luminal B, HER2-enriched and Basal-like) is prognostic and might predict treatment benefit5–7.